Pharmaceutical giant Pfizer has announced some changes in its leadership structure, following the company’s acquisition of drug maker Wyeth.

The executive leadership team now represents a combination of Pfizer and Wyeth leaders, including:

Amy Schulman, senior vice president and general counsel;

Jeffrey Kindler, CEO and chairman;

Frank D'Amelio, CFO and senior vice president of business operations;

Mikael Dolsten, president of BioTherapeutics Research & Development;

Freda Lewis-Hall, senior vice president and chief medical officer;

Martin Mackay, president, PharmaTherapeutics Research & Development;

Mary McLeod, senior vice president of human resources;

Ian Read, group president, Worldwide Biopharmaceutical Businesses;

Cavan Redmond, group president, Diversified Businesses;

Nat Ricciardi, president, manufacturing;

Bill Ringo, senior vice president, business development, strategy & innovation; and

Sally Susman, senior vice president, chief communications officer.

To further advance these objectives, Pfizer CEO Jeff Kindler has established an executive compliance committee, which he will chair. It will include Doug Lankler, who as chief compliance officer, reports directly to Jeffrey Kindler, and Chief Internal Auditor Hugh Donnelly, who reports both to the Audit Committee of the Board of Directors and to Frank D'Amelio. Also on the executive compliance committee will be D'Amelio, Read, Redmond, and Schulman.

“Pfizer will benefit greatly from the expertise of the executive leadership team, and the diversity of experience it represents,” Kindler said. “Our creation of the Executive compliance committee will serve as an important addition to our compliance infrastructure, and ensure the dedicated involvement of our senior-most leaders in our continuing efforts to fully integrate compliance and integrity into all that we do at Pfizer."

Pfizer is now a more diversified healthcare company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets.